Kinoxis Secures $2.5M CUREator+ Grant to Support CARES-X, A Phase 2a Australia-Based Clinical Study for KNX100 in Treating Agitation Associated with Dementia MELBOURNE, AUSTRALIA, 23 December 2024 – Kinoxis Therapeutics, an.
$14.5m Series B funding raised, with support from key investors Uniseed, UniSuper, University of Sydney, Stoic VC, Avicella Capital, as well as sophisticated investors..
KNX100 is a novel small molecule being developed as a transdiagnostic treatment for substance use disorders, including alcohol use disorder. A recently completed Phase.
KNX100 is a small molecule in development for the treatment of substance use disorders, including symptoms associated with withdrawal from opioids US$3.6 million awarded.
$5m funding round completed with existing shareholders Successful completion of key pre-clinical toxicology studies IND meeting and commencement of Phase 1 in first half.
University of Sydney spinout Kinoxis awarded NIH HEAL Initiative grant of up to $US4.6m Funding to support development of a potential treatment for opioid.
Spinout of technology from the University of Sydney Exclusive licence for the development of novel compounds for addiction Company founded with $3.9 million financing.
© Kinoxis Therapeutics | All Rights Reserved | Website by Graphink Design and Integrale Marketing